Clinical trials in Utrecht – page 5

625 clinical trials in Utrecht, The Netherlands across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Utrecht at a glance

625

clinical trials

Research sites5

Quick filters

625 trials in Utrecht

Open in trial search

Acute promyelocytic leukaemia

Recruiting

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo

The Netherlands

Participants:0–17 years
Substances:Arsenic Trioxide
Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Contact Research Centre

Neuroblastoma+2

Recruiting

Indocyanine Green and Near-Infrared Fluorescence for Lymph Node Removal in Children with Renal Tumours or Paratesticular Rhabdomyosarcoma

Registered drugNo placebo

Indocyanine Green and Near-Infrared Fluorescence for Lymph Node Removal in Children with Renal Tumours or Paratesticular Rhabdomyosarcoma

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Indocyanine Green
Sponsor:The University Of Birmingham

Contact Research Centre

HIV infection

Recruiting

A study to evaluate the effectiveness of lenalidomide, pyrimethamine, and topiramate in reducing the HIV reservoir in people living with HIV.

Registered drugNo placebo

A study to evaluate the effectiveness of lenalidomide, pyrimethamine, and topiramate in reducing the HIV reservoir in people living with HIV.

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

Registered drugNo placebo

Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Fludarabine Phosphate
Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Contact Research Centre

Neoplasm

Recruiting

Safety and Preliminary Efficacy of Oral GSK5460025A Alone or with Drug Combination in Adult Patients with dMMR/MSI‑H Colorectal Cancer

InvestigationalNo placebo

Safety and Preliminary Efficacy of Oral GSK5460025A Alone or with Drug Combination in Adult Patients with dMMR/MSI‑H Colorectal Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:GSK5460025A
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Crohn's disease

Recruiting

An observational study on the use of methotrexate in children and adolescents with Crohn's disease

Registered drugNo placebo

An observational study on the use of methotrexate in children and adolescents with Crohn's disease

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Methotrexate
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Amyotrophic lateral sclerosis

Recruiting

A study to evaluate the safety of VTx-002 in patients with amyotrophic lateral sclerosis.

InvestigationalNo placebo

A study to evaluate the safety of VTx-002 in patients with amyotrophic lateral sclerosis.

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:VTX-002
Sponsor:VectorY Therapeutics B.V.

Contact Research Centre

Bile duct cancer

Recruiting

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Brain neoplasm malignant

Recruiting

Study of the use of tasadenoturev for children and young adults with recurrent or resistant high-grade brain tumors

InvestigationalNo placebo

Study of the use of tasadenoturev for children and young adults with recurrent or resistant high-grade brain tumors

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Sponsor:Clinica Universidad De Navarra

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Utrecht

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on TTR amyloidosis and heart disease treatments, investigating new therapeutic approaches for cardiac conditions. Clinical trials evaluate novel medications for improving patient mobility and cardiac function.

Heart Disease Management
Cardiac Biomarkers
Treatment Efficacy

Research aims to enhance quality of life for patients with hereditary and wild-type ATTR cardiomyopathy.

02 Cancer Research

Comprehensive studies in gastric cancer, bladder cancer, and neuroblastoma, exploring innovative treatment combinations and diagnostic methods.

Immunotherapy Applications
Targeted Therapies
Diagnostic Imaging

Advanced trials combining established treatments with novel approaches to improve patient outcomes.

03 Neurological Disorders

Groundbreaking research in Amyotrophic Lateral Sclerosis and chronic inflammatory conditions, focusing on innovative treatments and disease modification strategies.

Gene-Targeted Therapies
Neurological Function
Disease Progression

Studies aim to develop effective treatments for rare and challenging neurological conditions.

Back to the Netherlands All countries